Brokerages expect Cancer Genetics, Inc. (NASDAQ:CGIX) to announce ($0.13) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Cancer Genetics’ earnings, with estimates ranging from ($0.13) to ($0.12). Cancer Genetics posted earnings of ($0.23) per share in the same quarter last year, which would suggest a positive year over year growth rate of 43.5%. The firm is scheduled to announce its next earnings results on Thursday, November 9th.

According to Zacks, analysts expect that Cancer Genetics will report full year earnings of ($0.87) per share for the current year, with EPS estimates ranging from ($0.90) to ($0.83). For the next fiscal year, analysts anticipate that the business will post earnings of $0.03 per share, with EPS estimates ranging from ($0.05) to $0.10. Zacks’ EPS averages are a mean average based on a survey of research firms that that provide coverage for Cancer Genetics.

Cancer Genetics (NASDAQ:CGIX) last announced its earnings results on Monday, August 14th. The medical research company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). Cancer Genetics had a negative return on equity of 48.78% and a negative net margin of 68.48%. The business had revenue of $6.60 million during the quarter, compared to the consensus estimate of $7.97 million. During the same period in the prior year, the business posted ($0.28) earnings per share. Cancer Genetics’s revenue was down 5.7% compared to the same quarter last year.

CGIX has been the subject of a number of recent analyst reports. Dawson James initiated coverage on Cancer Genetics in a report on Tuesday, June 27th. They set a “buy” rating for the company. Zacks Investment Research upgraded Cancer Genetics from a “sell” rating to a “buy” rating and set a $4.25 price target for the company in a report on Monday, July 17th. HC Wainwright set a $6.00 price target on Cancer Genetics and gave the stock a “buy” rating in a report on Tuesday, August 15th. Finally, Benchmark Co. initiated coverage on Cancer Genetics in a report on Monday, June 26th. They set a “speculative buy” rating and a $6.00 price target for the company. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $5.56.

In other news, Director John Pappajohn bought 100,000 shares of Cancer Genetics stock in a transaction dated Monday, June 12th. The stock was bought at an average cost of $3.75 per share, for a total transaction of $375,000.00. Following the purchase, the director now directly owns 2,542,519 shares in the company, valued at approximately $9,534,446.25. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders bought 272,370 shares of company stock valued at $933,479. 21.30% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Cancer Genetics by 61.9% in the second quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock valued at $2,041,000 after buying an additional 197,619 shares in the last quarter. Northern Trust Corp increased its stake in shares of Cancer Genetics by 61.0% in the second quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock valued at $127,000 after buying an additional 12,168 shares in the last quarter. Thompson Davis & CO. Inc. increased its stake in shares of Cancer Genetics by 5,465.0% in the second quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock valued at $440,000 after buying an additional 109,300 shares in the last quarter. KCG Holdings Inc. purchased a new stake in shares of Cancer Genetics during the first quarter valued at approximately $102,000. Finally, Renaissance Technologies LLC increased its stake in shares of Cancer Genetics by 44.8% in the first quarter. Renaissance Technologies LLC now owns 449,600 shares of the medical research company’s stock valued at $1,843,000 after buying an additional 139,200 shares in the last quarter. Institutional investors own 16.08% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Analysts Expect Cancer Genetics, Inc. (CGIX) Will Announce Earnings of -$0.13 Per Share” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/08/28/analysts-expect-cancer-genetics-inc-cgix-will-announce-earnings-of-0-13-per-share.html.

Shares of Cancer Genetics (CGIX) traded down 2.86% during midday trading on Wednesday, hitting $3.40. The stock had a trading volume of 67,989 shares. The firm’s market capitalization is $67.29 million. Cancer Genetics has a one year low of $1.10 and a one year high of $5.30. The firm’s 50-day moving average price is $3.67 and its 200-day moving average price is $3.51.

Cancer Genetics Company Profile

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Get a free copy of the Zacks research report on Cancer Genetics (CGIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Cancer Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc. and related stocks with our FREE daily email newsletter.